Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Cwm LLC

Cwm LLC increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 73.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,643 shares of the biotechnology company’s stock after purchasing an additional 14,655 shares during the quarter. Cwm LLC’s holdings in Exelixis were worth $899,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of EXEL. LSV Asset Management increased its position in shares of Exelixis by 107.7% during the 2nd quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock worth $129,511,000 after purchasing an additional 2,989,021 shares during the last quarter. Jupiter Asset Management Ltd. increased its position in shares of Exelixis by 148.2% during the 1st quarter. Jupiter Asset Management Ltd. now owns 2,267,894 shares of the biotechnology company’s stock worth $53,817,000 after purchasing an additional 1,354,062 shares during the last quarter. Swedbank AB acquired a new stake in shares of Exelixis during the 1st quarter worth about $22,455,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Exelixis during the 1st quarter worth about $10,906,000. Finally, Farallon Capital Management LLC increased its position in shares of Exelixis by 1.6% during the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after purchasing an additional 424,000 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of recent analyst reports. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Stifel Nicolaus raised their target price on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday. JMP Securities restated a “market outperform” rating and set a $29.00 target price on shares of Exelixis in a report on Friday, October 11th. Oppenheimer restated an “outperform” rating and set a $29.00 target price on shares of Exelixis in a report on Tuesday, July 30th. Finally, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Exelixis in a report on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.07.

Insider Transactions at Exelixis

In other news, EVP Dana Aftab sold 95,000 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the sale, the executive vice president now owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Exelixis news, Director Maria C. Freire sold 8,250 shares of Exelixis stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total transaction of $219,120.00. Following the transaction, the director now owns 91,007 shares of the company’s stock, valued at $2,417,145.92. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the transaction, the executive vice president now directly owns 520,990 shares in the company, valued at approximately $13,024,750. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 327,858 shares of company stock valued at $8,640,129. Corporate insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

Shares of EXEL opened at $28.90 on Friday. The stock has a 50-day simple moving average of $26.42 and a 200-day simple moving average of $23.83. The stock has a market capitalization of $8.76 billion, a PE ratio of 45.16, a PEG ratio of 0.54 and a beta of 0.54. Exelixis, Inc. has a 1 year low of $18.64 and a 1 year high of $29.75.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The business had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million. Analysts predict that Exelixis, Inc. will post 1.59 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.